ライフサイエンスコーパス: BCG vaccine

1 licensed vaccines, including live attenuated BCG vaccine.

2 erlooked contributors to poorer responses to BCG vaccine.

3 tter than the suboptimal Mycobacterium bovis BCG vaccine.

4 the partially effective Mycobacterium bovis BCG vaccine.

5 culosis than the currently utilized M. bovis BCG vaccine.

6 t levels comparable to protection induced by BCG vaccine.

7 quivalent to that of the Mycobacterium bovis BCG vaccine.

8 unized with conventional Mycobacterium bovis BCG vaccine.

9 , and positive controls received one dose of BCG vaccine.

10 ks, reductions similar to those generated by BCG vaccine.

11 succumbed within eight weeks to conventional BCG vaccine.

12 ogy than animals immunized with the parental BCG vaccines.

13 caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

14 tillation with the bacillus Calmette-Guerin (BCG) vaccine.

15 e than the present bacillus Calmette-Guerin (BCG) vaccine.

16 ($136 per DALY) were similar to that of the BCG vaccine ($51.86-220.39 per DALY).

17 es (67.5%; 95% CI 60.5-73.8) and highest for BCG vaccine (92.7%: 95% CI 88.1-95.6).

18 ella vaccine/tick-borne encephalitis vaccine/BCG vaccine: adjusted hazard ratio [HR], 0.66 [95% CI, 0

19 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have been available f

20 ously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated group, the rate of p

21 rified protein derivative (PPD) with M bovis BCG vaccine and environmental mycobacteria.

22 nd 138 cases per 100 000 person-years in the BCG vaccine and placebo groups, respectively, for an est

23 erculosis, C57BL/6 mice were vaccinated with BCG vaccine and then challenged 2 months later with one

24 Animals immunized with the recombinant BCG vaccines and challenged by aerosol with a highly vir

25 t also weakly virulent mycobacteria, such as BCG vaccines and environmental mycobacteria.

26 00 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to protect against tube

27 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorly understood.

28 We enrolled 92 infants: 50 had received BCG vaccine at birth and 42 at 6 weeks of age.

29 Infants delivered at home receive BCG vaccine at their first healthcare facility visit at

30 ells in adults who have already received the BCG vaccine, but aerosol delivery of this vaccine might

31 We demonstrate that BCG vaccine can be dried without traditional freezing an

32 uggesting that a single dose of an effective BCG vaccine can have a long duration of protection.

33 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection against fatal forms o

34 s immunized with their parental conventional BCG vaccine counterparts.

35 , a model in which parenterally administered BCG vaccine does not protect against tuberculosis.

36 In this trial, BCG vaccine efficacy persisted for 50 to 60 years, sugge

37 as a spray-dried nanomicroparticle aerosol, BCG vaccine exhibited high-efficiency delivery and perip

38 he live attenuated bacillus Calmette-Guerin (BCG) vaccine for the prevention of disease associated wi

39 ding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary greatly throughout th

40 local reactogenicity, EPD of OVA/LPS/CpG and BCG vaccine generated a comparable humoral immune respon

41 Data from 1483 participants in the BCG vaccine group and 1309 in the placebo group were ana

42 opsy, animals immunized with the recombinant BCG vaccines had fewer and smaller lesions in the lung,

43 Although the BCG vaccine has been one of the most widely used vaccine

44 BCG vaccine has shown consistently high efficacy against

45 ear even though the bacille Calmette Guerin (BCG) vaccine has been available for more than 75 years.

46 utic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly affected the current

47 We therefore assessed the immunogenicity of BCG vaccine in HIV-exposed infants who received BCG at b

48 tive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a

49 g approach for enhancing the efficacy of the BCG vaccine in humans.

50 potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea pig models of this d

51 pared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse

52 To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have stu

53 ins) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis protective immunity

54 and population heterogeneity may affect the BCG vaccine-induced T-cell response.

55 ycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was lost in the absence

56 (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturation in macrophages

57 d immunity approaching that conferred by the BCG vaccine is a feasible goal.

58 In tuberculosis-endemic regions, BCG vaccine is administered soon after birth, before in

59 The BCG vaccine is ineffective against adult tuberculosis.

60 duration of protection from tuberculosis of BCG vaccines is not known.

61 Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vaccine in

62 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the prevention of tuberc

63 Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has major limitations as

64 d local side effects of LPS/CpG adjuvant and BCG vaccine, leading to complete skin recovery.

65 ple, the live attenuated measles vaccine and BCG vaccine may reduce mortality from infections other t

66 BCG vaccine may reduce overall mortality by increasing r

67 y volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized

68 maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy.

69 nfected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days

70 Viability of BCG vaccine packaged in the caves and the mechanical str

71 Randomized trials assessing BCG vaccine protection against tuberculosis have widely

72 BCG vaccine protects against serious pediatric forms of

73 Little is known about how long the BCG vaccine protects against tuberculosis.

74 Mycobacterium bovis BCG vaccine provides only partial protection, and the sk

75 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but limited defense aga

76 lives per year, and improved efficacy of the BCG vaccine remains a World Health Organization priority

77 hlorophenyl)ethylene] reduces 6-month infant BCG vaccine response.

78 BCG vaccine scarring often is used as a surrogate marker

79 Thus, we found that, in older patients, BCG vaccine scarring was not associated with M. tubercul

80 nd Tice, we have constructed two recombinant BCG vaccines stably expressing and secreting the 30-kDa

81 Current data on which BCG vaccine strain induces the optimal immune response i

82 Previous studies suggest that BCG vaccine strain influences the immune response and pr

83 ch has been developed to replace the current BCG vaccine strain, and modified vaccinia virus Ankara (

84 The attenuated bacillus Calmette-Guerin (BCG) vaccine strain is derived from a virulent strain of

85 f the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an M. bovis PK+ mutant,

86 More than 20 genetically distinct BCG vaccine strains are in use worldwide.

87 Three commonly used Mycobacterium bovis BCG vaccine strains elicited different magnitudes of T-c

88 in the immune response induced by different BCG vaccine strains in newborn infants.

89 al were immunized at birth with one of three BCG vaccine strains.

90 d phenotypic variation between commonly used BCG vaccine strains.

91 Among patients who had not received the BCG vaccine, the rate of positivity by TST was 5.0% (62

92 nt evidence on the duration of protection by BCG vaccine, the screening of migrants and hard-to-reach

93 ased ability of the wild-type as well as the BCG vaccine to induce protective immunity.

94 ves who participated in a placebo-controlled BCG vaccine trial during 1935-1938 and who were still at

95 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried out in northern Malawi.

96 studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV),

97 t patterns of T-cell induction occurred when BCG vaccine was given at birth and at 6 weeks of age.

98 response induced by live Mycobacterium bovis BCG vaccine was greater than the response induced by any

99 ologous tumor cell-bacillus Calmette-Guerin (BCG) vaccine was conducted to determine whether surgical

100 tent than the current commercially available BCG vaccines, which were developed nearly a century ago.